Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. DFTX
8. KR
9. MSTR
10. HOOD

Go back to Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital

August 9, 2024 6:27 AM EDT

RBC Capital analyst Luca Issi lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $54.00 (from $60.00) while maintaining a Outperform rating.

The analyst comments "Following Phase II study that hit primary and all secondary endpoints (to be presented in 4Q) NTLA is planning to start... More